Target* | Polypill-based care | Usual care | RR† (95% CI) | ||
n/N (crude %) | Estimated† % (95% CI) | n/N (crude %) | Estimated† % (95% CI) | ||
BP | 865/1393 (62) | 54 (44 to 67) | 776/1347 (58) | 50 (41 to 62) | 1.08 (1.02 to 1.15)‡ |
SBP | 919/1393 (66) | 60 (52 to 70) | 831/1347 (62) | 56 (48 to 66) | 1.07 (1.01 to 1.13)‡ |
DBP | 1183/1393 (85) | 80 (71 to 90) | 1092/1347 (81) | 75 (67 to 85) | 1.05 (1.02 to 1.09)‡ |
LDL | 524/1343 (39) | 43 (35 to 51) | 443/1294 (34) | 38 (31 to 46) | 1.13 (1.02 to 1.25)‡ |
Antiplatelet§ | 1038/1086 (96) | 93 (88 to 98) | 1031/1078 (96) | 93 (89 to 98) | 1.00 (0.98 to 1.01) |
BP and LDL and antiplatelet§ | 331/1377 (24) | 24 (22 to 26) | 252/1336 (19) | 19 (17 to 21) | 1.27 (1.10 to 1.47)‡ |
*See table 1 for criteria.
†Estimated proportions and risk ratios were obtained from a log-binomial regression model as described in the methods section.
‡P<0.05 after Holm-Bonferroni correction for multiple testing of targets within the same guideline.
§Antiplatelet target only applicable to people with established cardiovascular disease.
BP, blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; RR, risk ratio; SBP, systolic blood pressure.